Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acetaminophen/Naltrexone - Allodynic Therapeutics

Next Previous
X
Search
Drug Profile

Acetaminophen/Naltrexone - Allodynic Therapeutics

Alternative Names: ALLOD 2; ALLOD-2H; ATNC 05

Latest Information Update: 28 Aug 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allodynic Therapeutics
  • Class Analgesics; Antimigraines; Ethers; Ketones
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Back pain; Migraine
  • No development reported Adjustment disorders

Most Recent Events

  • 28 Aug 2022 No recent reports of development identified for phase-I development in Adjustment-disorders in USA (PO, Capsule)
  • 05 Jul 2019 Phase-I clinical trials in Adjustment disorders in USA (PO) before July 2019
  • 18 Jul 2018 Allodynic Therapeutics completes a phase II trial in Migraine (Prevention) in USA (NCT03194555)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top